Gladstone's Center for Translational Advancement (GCTA) seeks a Research Associate II/III in human iPSC culture and stem cell technique to help develop and take charge of the large-scale stem cell culture, differentiation, and maintenance pipeline for our large-scale drug re-positioning effort. This candidate will have the opportunity to shape and take ownership of a critical component of the new center's drug re-purposing infrastructure.
Develop and maintain the pipeline for consistent production of multiple iPSC-derived cell types at scale.
Responsible for the culture, maintenance, propagation, and differentiation of the cell lines.
Differentiation of human iPSC lines into neural and glial cell types, using consensus protocols.
Provide regular quality assurance reports detailing culture quality, consistency, and cleanliness.
Provide training to incoming researchers where necessary.
Exercise resourcefulness, creativity and proactivity to seek out answers to unforeseen difficulties or problems outside range of expertise.
Implement operational modifications where necessary to improve accuracy, efficiency, and cost-effectiveness
BS or MS in a field of Biological Sciences required.
2+ years' experience in a laboratory setting applying human stem cell culture techniques.
Must be skilled in pluripotent human stem cell culture, propagation and differentiation, with excellent aseptic technique.
Large-scale drug screening experience preferred.
Exceptional organizational and documentation skills.
Previous experience starting a lab or building a cell-culture program would be ideal.
The ideal candidate will be personally motivated to accelerate the development of underutilized compounds into treatments for under-treated diseases. S/he will thrive in an environment of team science, where many minds rally around a common goal, in a culture of support and collaboration. The objective of the person in this position will be to build and run a robust, large-scale pipeline for consistent production of multiple brain cell types from human iPSCs, for screening with FDA-approved compounds, with the goal of re-purposing those compounds for new treatments for neurological and neurodegenerative diseases.
About the Gladstone Center for Translational Advancement
The Gladstone Center for Translational Advancement (GCTA) was created in 2017 to find unforeseen uses for existing drugs. Seeking new uses for FDA-approved drugs, which have already passed safety tests, can help bring treatments to patients more quickly. This "drug re-purposing" approach drastically lowers the cost and shortens the timeline of drug development.
Headed by Senior Investigator Yadong Huang, MD, PhD, the center provides crucial resources to develop re-purposed drugs that target diseases of the central nervous system, the heart, and the immune system. The center aims to accelerate the conversion of basic research findings into efficient clinical candidates and, ultimately, medical applications.
The center includes three major components:
Build a drug repositioning database of up to 15,000 compounds using human cells derived from induced pluripotent stem cells (iPSCs). The database will outline how each drug affects healthy and diseased human genes.
Establish infrastructure to test repurposed drugs in cell culture and animal models for potency, pharmacokinetic (PK), and pharmacodynamic (PD) studies in collaboration with Gladstone Senior Investigator Sheng Ding and the School of Pharmaceutical Sciences at the Tsinghua University in Beijing.
Promote human clinical trials of re-purposed drugs, in collaboration with medical centers and pharmaceutical companies in the US and abroad.
Title and salary will be commensurate with education and title.
Be a part of big ideas and consider Gladstone. Your difference will make a difference in human health.
Gladstone is an equal opportunity employer.